NUCLEOSOMICS®- TRANSLATING EPIGENETIC BIOMARKERS INTO CLINICAL DIAGNOSTICS


Herzog M*, Josseaux E, Scoubeau K, Pamart D, Chapelier M, Cuvelier G, Eccleston M, Micallef J Belgian Volition SA. Centre Technologique 20A Rue Du Seminaire, Be-5000, Namur, Belgium.

*Correspondence: m.herzog@volitionrx.com, +32 81 72 56 46

METHODOLOGY

Nucleosomics® combines cutting edge epigenetic profiling with a simple, low cost immunoassay technology to improve clinical diagnosis of cancer.


Immunohistochemistry studies show genome-wide epigenetic changes in cancer tissue and have identified histo-oncoproteins - histone modifications linked to cancer. In addition, nucleosomes (147 base pair DNA sequences wrapped around four pairs of histone proteins) are released as chromatin fragments on cell death. Total levels of cell free nucleosomes can be elevated by inflammation, infectious disease and cancer, limiting diagnostic utility. However, circulating cell-free, nucleosome bound DNA fragments contain mutations found in cancer tissue from the same patients suggesting a tumor chromatin origin for, at least some, circulating nucleosomes. Profiling of global levels of epigenetic modifications in nucleosomes can provide disease specific diagnostic information.




FIVE ASSAY FAMILIES

Five assay families, with multiple assays: hundreds of possible panel combinations


- NuQ®-X
 specific DNA
 modifications
- NuQ®-V
 histone variants
- NuQ®-M
 histone modifications
- NuQ®-A
 nucleosome-protein
 adducts
- NuQ®-T total nucleosomes



COLORECTAL CANCER



PANCREATIC CANCER



LUNG CANCER

